Trial Outcomes & Findings for A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT) (NCT NCT01618669)
NCT ID: NCT01618669
Last Updated: 2016-02-08
Results Overview
SPECT scans were reviewed in a blinded fashion by 3 independent expert readers using the 17-segment model for standardized myocardial segmentation. At rest and stress, each segment was scored on a 0 (normal) to 4 (absent contrast/radiotracer uptake) scale by each of the 3 blinded readers according to the amount of contrast or radiotracer the myocardium in the segment absorbed. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect. The number of segments with reversible defects was categorized as absence (0 - 1 reversible segments) or presence (≥ 2 defects reversible segments) of ischemia. Each reader was defined as having self-agreement based upon identical categorization of a given participant as absent or present for ischemia for both the initial and second stress visits. Majority agreement is if at least 2 out of the 3 blinded readers demonstrated self-agreement for a given participant.
COMPLETED
PHASE3
1147 participants
Day 1 (rest scan and first stress scan) and Day 2 -15 (second stress scan)
2016-02-08
Participant Flow
This study was conducted at 49 sites in a total of 3 countries including the United States (44 sites), Argentina (4 sites) and Peru (1 site).
At Baseline, patients meeting all inclusion/exclusion criteria completed single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) while at rest. Participants then underwent a Bruce or modified Bruce exercise protocol; those unable to reach 85% maximum predicted heart rate and/or 5 metabolic equivalents were randomized.
Participant milestones
| Measure |
Regadenoson After Peak Exercise
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT myocardial perfusion imaging (MPI). One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
|---|---|---|
|
Overall Study
STARTED
|
578
|
569
|
|
Overall Study
Received Treatment
|
575
|
567
|
|
Overall Study
COMPLETED
|
544
|
546
|
|
Overall Study
NOT COMPLETED
|
34
|
23
|
Reasons for withdrawal
| Measure |
Regadenoson After Peak Exercise
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT myocardial perfusion imaging (MPI). One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
|---|---|---|
|
Overall Study
Lost to Follow-up
|
1
|
1
|
|
Overall Study
Randomized but Never Received Study Drug
|
3
|
2
|
|
Overall Study
Adverse Event
|
16
|
7
|
|
Overall Study
Protocol Violation
|
5
|
3
|
|
Overall Study
Withdrawal by Subject
|
9
|
9
|
|
Overall Study
Miscellaneous Reason
|
0
|
1
|
Baseline Characteristics
A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
Baseline characteristics by cohort
| Measure |
Regadenoson After Peak Exercise
n=575 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone
n=567 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Total
n=1142 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
61.9 years
STANDARD_DEVIATION 11.45 • n=99 Participants
|
61.9 years
STANDARD_DEVIATION 11.19 • n=107 Participants
|
61.9 years
STANDARD_DEVIATION 11.32 • n=206 Participants
|
|
Sex: Female, Male
Female
|
234 Participants
n=99 Participants
|
239 Participants
n=107 Participants
|
473 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
341 Participants
n=99 Participants
|
328 Participants
n=107 Participants
|
669 Participants
n=206 Participants
|
|
Bruce Exercise Group
Standard Bruce Exercise
|
448 participants
n=99 Participants
|
442 participants
n=107 Participants
|
890 participants
n=206 Participants
|
|
Bruce Exercise Group
Modified Bruce Exercise
|
90 participants
n=99 Participants
|
93 participants
n=107 Participants
|
183 participants
n=206 Participants
|
|
Maximum Metabolic Equivalents Achieved
|
5.45 metabolic equivalents
STANDARD_DEVIATION 2.284 • n=99 Participants
|
5.37 metabolic equivalents
STANDARD_DEVIATION 2.331 • n=107 Participants
|
5.41 metabolic equivalents
STANDARD_DEVIATION 2.307 • n=206 Participants
|
PRIMARY outcome
Timeframe: Day 1 (rest scan and first stress scan) and Day 2 -15 (second stress scan)Population: Full Analysis Set
SPECT scans were reviewed in a blinded fashion by 3 independent expert readers using the 17-segment model for standardized myocardial segmentation. At rest and stress, each segment was scored on a 0 (normal) to 4 (absent contrast/radiotracer uptake) scale by each of the 3 blinded readers according to the amount of contrast or radiotracer the myocardium in the segment absorbed. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect. The number of segments with reversible defects was categorized as absence (0 - 1 reversible segments) or presence (≥ 2 defects reversible segments) of ischemia. Each reader was defined as having self-agreement based upon identical categorization of a given participant as absent or present for ischemia for both the initial and second stress visits. Majority agreement is if at least 2 out of the 3 blinded readers demonstrated self-agreement for a given participant.
Outcome measures
| Measure |
Regadenoson After Peak Exercise
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 1
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 2
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
|
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
|
|---|---|---|---|---|---|---|
|
Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans
|
0.92 proportion of participants
Interval 0.89 to 0.94
|
0.95 proportion of participants
Interval 0.93 to 0.97
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Within 1 hour for ECG events and up to 24 hours for adverse events after administration of regadenosonPopulation: Safety analysis set (all randomized participants who received at least 1 dose of regadenoson study drug)
A clinically significant cardiac event is defined as: * Any of the following events found on the Holter electrocardiogram (ECG)/12-Lead ECG within 1 hour after regadenoson administration: * ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes, ventricular flutter), * ST-T depression (\> 2 mm), * ST-T elevation (≥1 mm), * Atrioventricular (AV) block (2:1 AV block, AV Mobitz I, AV Mobitz II, complete heart block) * sinus arrest \> 3 seconds in duration Or * a treatment-emergent adverse event (TEAE) per the Medical Dictionary for Regulatory Activities (MedDRA) Standardised MedDRA Queries (SMQ) (Narrow Scope) for myocardial infarction Or * a TEAE preferred term of angina unstable within 24 hours of regadenoson administration.
Outcome measures
| Measure |
Regadenoson After Peak Exercise
n=575 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone
n=544 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 1
n=567 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 2
n=548 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
|
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
|
|---|---|---|---|---|---|---|
|
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Any Event
|
3.0 percentage of participants
|
0.9 percentage of participants
|
0.5 percentage of participants
|
0.4 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Any TEAE per SMQ for Myocardial Infarction
|
0.3 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Acute Coronary Syndrome
|
0.2 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Any Holter/12-Lead ECG Abnormality
|
2.8 percentage of participants
|
0.9 percentage of participants
|
0.5 percentage of participants
|
0.4 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Sustained Ventricular Tachycardia
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Ventricular Fibrillation or Ventricular Flutter
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Torsade de Pointes
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
ST-T Depression (≥ 2 mm)
|
2.3 percentage of participants
|
0.6 percentage of participants
|
0.4 percentage of participants
|
0.4 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
ST-T Elevation (≥ 1 mm)
|
0.5 percentage of participants
|
0.4 percentage of participants
|
0.2 percentage of participants
|
0.0 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
2:1 AV Block
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Mobitz I Second Degree AV Block
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Mobitz II Second Degree AV Block
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Complete Heart Block
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Pause > 3.0 seconds
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Myocardial Infarction
|
0.2 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Adverse Event of Angina Unstable
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
0.0 percentage of participants
|
—
|
—
|
SECONDARY outcome
Timeframe: Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)Population: Full Analysis Set
The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as absence (0 to 1 reversible segments) or presence (≥ 2 reversible defects) of ischemia, the proportion of participants with agreement in the presence and absence of ischemia between the first and second stress scans was calculated.
Outcome measures
| Measure |
Regadenoson After Peak Exercise
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 1
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 2
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
|
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
|
|---|---|---|---|---|---|---|
|
Proportion of Participants With Agreement in the Assessment of Absence or Presence of Ischemia Between First and Second Stress Scans
|
0.75 proportion of participants
Interval 0.68 to 0.83
|
0.77 proportion of participants
Interval 0.67 to 0.86
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)Population: Full Analysis Set
The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as 0 to 1, 2 to 4, or ≥ 5 reversible segments, the proportion of participants with agreement in the three ischemia categories between the first and second stress scans was to be calculated. In the reported data, these proportions only include the 0-1 and 2-4 categories; the ≥ 5 category was not included because there were no participants in this category for the Regadenoson Alone group for the initial stress MPI.
Outcome measures
| Measure |
Regadenoson After Peak Exercise
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 1
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 2
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
|
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
|
|---|---|---|---|---|---|---|
|
Proportion of Participants With Agreement in the Assessment of Reversible Defects in 3 Categories of Ischemia Between First and Second Stress Scans
|
0.73 proportion of participants
Interval 0.69 to 0.77
|
0.75 proportion of participants
Interval 0.71 to 0.78
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)Population: Full Analysis Set
The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. Each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed: * 0: normal perfusion * 1: slightly reduced contrast/radiotracer uptake * 2: moderately reduced contrast/radiotracer uptake * 3: severely reduced contrast/radiotracer uptake * 4: absent contrast/radiotracer uptake. The Summed Stress Score (SSS) was calculated as the sum of the stress scores across the 17 segments. The mean value (rounded to the nearest integer) across the 3 readers was computed and the SSS was categorized into 4 group categorical variables based on the score: 0 to 3, 4 to 7, 8 to 11, and ≥ 12. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated.
Outcome measures
| Measure |
Regadenoson After Peak Exercise
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 1
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 2
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
|
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
|
|---|---|---|---|---|---|---|
|
Proportion of Participants With Agreement in the Summed Stress Score (SSS) Between First and Second Stress Scans
|
0.86 proportion of participants
|
0.84 proportion of participants
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)Population: Full Analysis Set
The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. At rest and stress, each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed: * 0: normal perfusion * 1: slightly reduced contrast/ uptake * 2: moderately reduced contrast/uptake * 3: severely reduced contrast/uptake * 4: absent contrast/uptake. SSS was calculated as the sum of the stress scores across the 17 segments and the Summed Rest Score (SRS) was calculated as the sum of the rest scores across the 17 segments. The Summed Difference Score (SDS) is the difference in the SSS and SRS (SSS - SRS). The mean value (rounded to the nearest integer) across the 3 readers was computed and the SDS was categorized into 3 categorical variables based on the score: 0 to 6, 7 to 13 and ≥ 14. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated.
Outcome measures
| Measure |
Regadenoson After Peak Exercise
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 1
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 2
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
REG Alone: MPI 2 SDS 7-13
n=535 Participants
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
|
REG Alone: MPI 2 SDS ≥ 14
n=535 Participants
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
|
|---|---|---|---|---|---|---|
|
Proportion of Participants With Agreement in the Summed Difference Score (SDS) Between First and Second Stress Scans
MPI 1 SDS 0-6
|
531 participants
|
4 participants
|
0 participants
|
527 participants
|
3 participants
|
0 participants
|
|
Proportion of Participants With Agreement in the Summed Difference Score (SDS) Between First and Second Stress Scans
MPI 1 SDS 7-13
|
0 participants
|
3 participants
|
0 participants
|
2 participants
|
3 participants
|
0 participants
|
|
Proportion of Participants With Agreement in the Summed Difference Score (SDS) Between First and Second Stress Scans
MPI 1 SDS ≥ 14
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Day 1 (stress MPI 1) and Day 2-15 (stress MPI 2)Population: Full Analysis Set
Each reader evaluated the initial stress SPECT MPI scan compared to the participant's second stress SPECT MPI scan (blinded at time of the evaluation) for whether there was Less (-1), the Same (0) or More (1) reversible perfusion defects. The median assessment of the 3 blinded readers was used to summarize the number of participants in each category.
Outcome measures
| Measure |
Regadenoson After Peak Exercise
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 1
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 2
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
|
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
|
|---|---|---|---|---|---|---|
|
Participants With Less, the Same, or More Reversible Perfusion Defects Shown by the First Stress Scan When Compared to the Second Stress Scan
Less Reversible Perfusion Defects
|
57 participants
|
49 participants
|
—
|
—
|
—
|
—
|
|
Participants With Less, the Same, or More Reversible Perfusion Defects Shown by the First Stress Scan When Compared to the Second Stress Scan
Same Number of Reversible Perfusion Defects
|
441 participants
|
459 participants
|
—
|
—
|
—
|
—
|
|
Participants With Less, the Same, or More Reversible Perfusion Defects Shown by the First Stress Scan When Compared to the Second Stress Scan
More Reversible Perfusion Defects
|
40 participants
|
27 participants
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)Population: Full Analysis Set
The image quality for each scan was rated by each independent reader as 1 = Poor, 2 = Fair, 3 = Good, 4 = Excellent. Based on the median rating of overall image quality across the three readers, the number of participants with each rating is reported for each scan.
Outcome measures
| Measure |
Regadenoson After Peak Exercise
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 1
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 2
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
|
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
|
|---|---|---|---|---|---|---|
|
Overall Assessment of Image Quality
Stress MPI 2: Fair
|
43 participants
|
37 participants
|
—
|
—
|
—
|
—
|
|
Overall Assessment of Image Quality
Stress MPI 2: Poor
|
0 participants
|
0 participants
|
—
|
—
|
—
|
—
|
|
Overall Assessment of Image Quality
Rest MPI: Excellent
|
140 participants
|
157 participants
|
—
|
—
|
—
|
—
|
|
Overall Assessment of Image Quality
Rest MPI: Good
|
307 participants
|
308 participants
|
—
|
—
|
—
|
—
|
|
Overall Assessment of Image Quality
Rest MPI: Fair
|
91 participants
|
70 participants
|
—
|
—
|
—
|
—
|
|
Overall Assessment of Image Quality
Rest MPI: Poor
|
0 participants
|
0 participants
|
—
|
—
|
—
|
—
|
|
Overall Assessment of Image Quality
Stress MPI 1: Excellent
|
224 participants
|
211 participants
|
—
|
—
|
—
|
—
|
|
Overall Assessment of Image Quality
Stress MPI 1: Good
|
287 participants
|
291 participants
|
—
|
—
|
—
|
—
|
|
Overall Assessment of Image Quality
Stress MPI 1: Fair
|
27 participants
|
33 participants
|
—
|
—
|
—
|
—
|
|
Overall Assessment of Image Quality
Stress MPI 1: Poor
|
0 participants
|
0 participants
|
—
|
—
|
—
|
—
|
|
Overall Assessment of Image Quality
Stress MPI 2: Excellent
|
192 participants
|
205 participants
|
—
|
—
|
—
|
—
|
|
Overall Assessment of Image Quality
Stress MPI 2: Good
|
303 participants
|
293 participants
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)Population: Full analysis set participants who have planar images available for each scan
Image quality was assessed through radiotracer uptake in the heart (target organ) compared to liver, gut and combined liver plus gut (background interference).
Outcome measures
| Measure |
Regadenoson After Peak Exercise
n=514 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone
n=525 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 1
n=518 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 2
n=523 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
|
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
|
|---|---|---|---|---|---|---|
|
Target to Background Radiotracer Uptake Ratios From the First and Second Stress Scans
Heart-to-Gut
|
1.12 ratio
Standard Deviation 0.436
|
0.99 ratio
Standard Deviation 0.399
|
1.05 ratio
Standard Deviation 0.428
|
0.99 ratio
Standard Deviation 0.387
|
—
|
—
|
|
Target to Background Radiotracer Uptake Ratios From the First and Second Stress Scans
Heart-to-Liver
|
1.05 ratio
Standard Deviation 0.399
|
0.94 ratio
Standard Deviation 0.373
|
0.96 ratio
Standard Deviation 0.365
|
0.95 ratio
Standard Deviation 0.362
|
—
|
—
|
|
Target to Background Radiotracer Uptake Ratios From the First and Second Stress Scans
Heart-to-(Liver/Gut)
|
1.02 ratio
Standard Deviation 0.296
|
0.90 ratio
Standard Deviation 0.260
|
0.94 ratio
Standard Deviation 0.274
|
0.91 ratio
Standard Deviation 0.259
|
—
|
—
|
SECONDARY outcome
Timeframe: Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)Population: Full Analysis Set
Each reader assessed the sub-diaphragmatic radiotracer interference with cardiac image quality using a 4-point scale of 0 = none, 1 = slight, 2 = moderate or 3 = severe for each stress SPECT MPI. The median rating across the 3 readers was used to summarize the percentage of scans with interference.
Outcome measures
| Measure |
Regadenoson After Peak Exercise
n=284 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone
n=284 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 1
n=270 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 2
n=270 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
|
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
|
|---|---|---|---|---|---|---|
|
Percentage of Scans With Subdiaphragmatic Interference
Slight
|
71.8 percentage of stress MPI scans
|
63.7 percentage of stress MPI scans
|
68.1 percentage of stress MPI scans
|
67.4 percentage of stress MPI scans
|
—
|
—
|
|
Percentage of Scans With Subdiaphragmatic Interference
None
|
0.4 percentage of stress MPI scans
|
0.0 percentage of stress MPI scans
|
0.0 percentage of stress MPI scans
|
0.0 percentage of stress MPI scans
|
—
|
—
|
|
Percentage of Scans With Subdiaphragmatic Interference
Moderate
|
27.5 percentage of stress MPI scans
|
36.3 percentage of stress MPI scans
|
31.5 percentage of stress MPI scans
|
32.6 percentage of stress MPI scans
|
—
|
—
|
|
Percentage of Scans With Subdiaphragmatic Interference
Severe
|
0.4 percentage of stress MPI scans
|
0.0 percentage of stress MPI scans
|
0.4 percentage of stress MPI scans
|
0.0 percentage of stress MPI scans
|
—
|
—
|
SECONDARY outcome
Timeframe: Day 1 (stress MPI 1) and Day - 15 (stress MPI 2)Population: Full Analysis Set
The number of cardiac segments obscured by the sub-diaphragmatic activity by group by stress SPECT MPI scan and by reader is reported.
Outcome measures
| Measure |
Regadenoson After Peak Exercise
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 1
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 2
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
|
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
|
|---|---|---|---|---|---|---|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 3
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.2 percentage of segments
|
0.6 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 4
|
34.4 percentage of segments
|
35.1 percentage of segments
|
32.5 percentage of segments
|
32.5 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 6
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 8
|
0.0 percentage of segments
|
0.2 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 9
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.4 percentage of segments
|
0.4 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 12
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 13
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 14
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 17
|
0.4 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 3
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 4
|
14.1 percentage of segments
|
16.7 percentage of segments
|
17.9 percentage of segments
|
17.2 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 9
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 10
|
16.0 percentage of segments
|
17.8 percentage of segments
|
18.5 percentage of segments
|
18.9 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 1
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 2
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 3
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 4
|
33.6 percentage of segments
|
37.2 percentage of segments
|
34.2 percentage of segments
|
37.4 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 5
|
9.7 percentage of segments
|
8.4 percentage of segments
|
7.9 percentage of segments
|
7.7 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 6
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 7
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 8
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 9
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 10
|
31.6 percentage of segments
|
35.5 percentage of segments
|
32.3 percentage of segments
|
36.3 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 11
|
9.5 percentage of segments
|
8.2 percentage of segments
|
7.5 percentage of segments
|
7.5 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 12
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 13
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 14
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 15
|
1.7 percentage of segments
|
0.9 percentage of segments
|
2.4 percentage of segments
|
2.1 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 16
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.2 percentage of segments
|
0.2 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 17
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 1
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 2
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.2 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 5
|
1.1 percentage of segments
|
0.4 percentage of segments
|
0.7 percentage of segments
|
0.7 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 7
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 10
|
12.6 percentage of segments
|
11.9 percentage of segments
|
13.8 percentage of segments
|
13.1 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 11
|
0.0 percentage of segments
|
0.2 percentage of segments
|
0.6 percentage of segments
|
0.2 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 15
|
9.1 percentage of segments
|
8.7 percentage of segments
|
10.5 percentage of segments
|
9.5 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 16
|
0.0 percentage of segments
|
0.2 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 1
|
0.0 percentage of segments
|
0.2 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 2
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 5
|
0.6 percentage of segments
|
0.4 percentage of segments
|
0.7 percentage of segments
|
0.2 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 6
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 7
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 8
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 11
|
0.7 percentage of segments
|
0.2 percentage of segments
|
0.6 percentage of segments
|
0.2 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 12
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 13
|
0.2 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 14
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
0.0 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 15
|
13.9 percentage of segments
|
13.8 percentage of segments
|
13.1 percentage of segments
|
14.6 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 16
|
0.4 percentage of segments
|
0.7 percentage of segments
|
0.4 percentage of segments
|
0.2 percentage of segments
|
—
|
—
|
|
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 17
|
0.9 percentage of segments
|
0.9 percentage of segments
|
0.7 percentage of segments
|
0.6 percentage of segments
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 24 hours after study drug administration for each stress MPI (Day 1 and Day 2-15)Population: Safety Analysis Set.
An adverse event is considered "serious" if, in the view of either the investigator or sponsor, it results in any of the following outcomes: * Results in death, * Is life threatening, * Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, * Results in congenital anomaly, or birth defect, * Requires inpatient hospitalization or leads to prolongation of hospitalization * Other medically important events. Relationship to study drug was assessed by the investigator.
Outcome measures
| Measure |
Regadenoson After Peak Exercise
n=575 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone
n=544 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 1
n=567 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 2
n=548 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
|
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
|
|---|---|---|---|---|---|---|
|
Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
Drug-related adverse event
|
291 participants
|
298 participants
|
319 participants
|
308 participants
|
—
|
—
|
|
Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
Any adverse event
|
302 participants
|
317 participants
|
329 participants
|
323 participants
|
—
|
—
|
|
Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
Deaths
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
—
|
—
|
|
Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
Serious adverse events
|
5 participants
|
2 participants
|
1 participants
|
1 participants
|
—
|
—
|
|
Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
Drug-related serious adverse events
|
2 participants
|
0 participants
|
0 participants
|
0 participants
|
—
|
—
|
|
Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
Adverse events leading to discontinuation
|
13 participants
|
0 participants
|
5 participants
|
1 participants
|
—
|
—
|
|
Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
Drug-related AEs leading to discontinuation
|
9 participants
|
0 participants
|
5 participants
|
0 participants
|
—
|
—
|
Adverse Events
Regadenoson After Peak Exercise: MPI 1
Regadenoson After Peak Exercise: MPI 2
Regadenoson Alone: MPI 1
Regadenoson Alone: MPI 2
Serious adverse events
| Measure |
Regadenoson After Peak Exercise: MPI 1
n=575 participants at risk
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson After Peak Exercise: MPI 2
n=544 participants at risk
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 1
n=567 participants at risk
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 2
n=548 participants at risk
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
|---|---|---|---|---|
|
Cardiac disorders
Acute coronary syndrome
|
0.17%
1/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.18%
1/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
|
Cardiac disorders
Myocardial infarction
|
0.17%
1/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
|
Cardiac disorders
Myocardial ischaemia
|
0.17%
1/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.18%
1/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
|
Eye disorders
Vision blurred
|
0.17%
1/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.18%
1/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
|
Investigations
Anticoagulation drug level below therapeutic
|
0.00%
0/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.18%
1/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
|
Investigations
Hepatic enzyme abnormal
|
0.17%
1/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
|
Nervous system disorders
Dizziness
|
0.17%
1/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
|
Nervous system disorders
Speech disorder
|
0.17%
1/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
|
Nervous system disorders
Syncope
|
0.17%
1/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
Other adverse events
| Measure |
Regadenoson After Peak Exercise: MPI 1
n=575 participants at risk
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson After Peak Exercise: MPI 2
n=544 participants at risk
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 1
n=567 participants at risk
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
Regadenoson Alone: MPI 2
n=548 participants at risk
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
|
|---|---|---|---|---|
|
Gastrointestinal disorders
Abdominal pain upper
|
5.4%
31/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
6.4%
35/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
6.2%
35/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
6.2%
34/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
|
Gastrointestinal disorders
Nausea
|
7.5%
43/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
8.1%
44/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
7.9%
45/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
7.5%
41/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
|
General disorders
Chest discomfort
|
6.4%
37/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
6.1%
33/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
9.5%
54/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
7.8%
43/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
|
Nervous system disorders
Dizziness
|
18.4%
106/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
13.8%
75/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
15.7%
89/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
14.8%
81/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
|
Nervous system disorders
Headache
|
14.8%
85/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
19.9%
108/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
24.2%
137/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
21.5%
118/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
24.5%
141/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
23.0%
125/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
28.4%
161/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
27.7%
152/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
|
Vascular disorders
Flushing
|
8.2%
47/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
14.3%
78/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
13.9%
79/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
12.6%
69/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
|
Additional Information
Senior Medical Director, Medical Affairs
Astellas Pharma Global Development, Inc. (APGD)
Results disclosure agreements
- Principal investigator is a sponsor employee Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data or 18 months after data-lock, whichever is first. Sponsor must receive a site's manuscript at least 45 days prior to publication for review and comment. Sponsor may delay the publication for up to 60 days to seek patent protection.
- Publication restrictions are in place
Restriction type: OTHER